THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Use of Lactobacillus sakei WIKIM30 (Accession No. KCCM11878P) or its culture in the manufacture of a pharmaceutical composition for prevention or treatment of cancer.

2. The use according to claim 1,

wherein the Lactobacillus sakei WIKIM30 has the nucleic acid sequence of SEQ ID NO: 1.

3. The use according to claim 1 or claim 2,

wherein the cancer is any one cancer selected from the group consisting of colorectal cancer, skin cancer, lung cancer, pancreatic cancer, liver cancer and bladder cancer.

4. The use according to claim 3,

wherein the lung cancer is non-small cell lung cancer.

5. The use according to claim 3,

wherein the skin cancer is melanoma.

6. The use according to any one of claims 1 to 5,

wherein the composition is administrable by oral administration or

parenteral administration.

7. The use according to claim 6,

wherein the parenteral administration is intravenous injection administration.

8. The use according to any one of claims 1 to 7,

wherein the composition is in a living cell form.

9. Use of Lactobacillus sakei WIKIM30 (Accession No. KCCM11878P) or its culture in the manufacture of a food composition for prevention or improvement of cancer.

10. The use according to claim 9,

wherein the food is health functional food.

11. The use according to claim 9 or claim 10,

wherein the food is any one food selected from the group consisting of bread, rice cake, candy, chocolate, gum, ice cream, milk, cheese, processed meat products, processed fish products, kimchi, soy sauce, soybean paste, red pepper paste, black bean paste, fermented soybean paste, vinegar, ketchup, curry, dressing, beverages and fermented milk.

12. Use of Lactobacillus sakei WIKIM30 (Accession No. KCCM11878P) or its culture in the manufacture of a food additive composition for prevention or improvement of cancer.

13. Use of Lactobacillus sakei WIKIM30 (Accession No. KCCM11878P) or its culture in the manufacture of a feed composition for prevention or improvement of cancer in livestock.

14. The use according to claim 13,

wherein the livestock is any one selected from the group consisting of pig, cow, horse, sheep, rabbit, goat, mouse, hamster, guinea pig, dog, cat, chicken, turkey, duck, goose, pheasant, quail, carp, crucian carp and trout.

15. Use of Lactobacillus sakei WIKIM30 (Accession No. KCCM11878P) or its culture in the manufacture of a feed additive composition for prevention or improvement of cancer in livestock.

16. Use of Lactobacillus sakei WIKIM30 (Accession No. KCCM11878P) or its culture in the manufacture of a the composition of any one of claims 1 to 8 for prevention or treatment of cancer in a subject other than humans.

17. The use according to claim 16,

wherein the composition is formulated for administration at a dose of 0.1 ㎖ of Lactobacillus sakei WIKIM30 at a concentration of 1×10^{10} CFU/㎖ by intravenous injection.

18. The use according to claim 17,

wherein the composition is formulated for single administration.